Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15429 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Cristina Rebordosa und 11 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Barcelona, Spain. Hauptthemen laut MEDLINE: Acute Kidney Injury, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Ketoacidosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To estimate risks of diabetic ketoacidosis (DKA), acute liver injury (ALI), acute kidney injury (AKI), chronic kidney disease (CKD), severe complications of urinary tract infection (UTI) and genital infection (GI) among patients with type 2 diabetes initiating empagliflozin versus those initiating a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. Materials and Methods In this large multinational, observational, new‐user cohort study in UK, Danish and US healthcare data sources, patients initiated empagliflozin or a DPP‐4 inhibitor between August 2014 and August 2019, were aged ≥18 years, and had ≥12 months' continuous health plan enrolment. Incidence rates by exposure and incidence rate ratios, adjusted for propensity‐score deciles, were calculated.
Results
In total, 64 599 empagliflozin initiators and 203 315 DPP‐4 inhibitor initiators were included. There was an increased risk [pooled adjusted incidence rate ratios (95% confidence interval)] of DKA [2.19 (1.74‐2.76)] and decreased risks of ALI [0.77 (0.50‐1.19) in patients without predisposing conditions of liver disease; 0.70 (0.56‐0.88) in all patients] and AKI [0.54 (0.41‐0.73)]. In the UK data, there was an increased risk of GI [males: 4.04 (3.46‐4.71); females: 3.24 (2.81‐3.74)] and decreased risks of CKD [0.53 (0.43‐0.65)] and severe complications of UTI [0.51 (0.37‐0.72)]. The results were generally consistent in subgroup and sensitivity analyses.
Conclusions
Compared with DDP‐4 inhibitor use, empagliflozin use was associated with increased risks of DKA and GI and decreased risks of ALI, AKI, CKD and severe complications of UTI. These associations are consistent with previous studies and known class effects of sodium‐glucose cotransporter 2 inhibitors, including renoprotective effects and beneficial effects on alanine aminotransferase levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RTI Health Solutions, Barcelona, Spain.
- Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- Carelon Research, Wilmington, Delaware, USA.
- Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
- The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, Michigan, USA.
ORCID-Profile: Cristina Rebordosa
Förderung
- Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance
Zitieren
APA
Rebordosa, C., Thomsen, R. W., Tave, A. K., Madsen, M., Beachler, D. C., Martinez, D., Garcia-Esteban, R., Plana, E., Tormos, A., Farsani, S. F., Perez-Gutthann, S., & Pladevall-Vila, M. (2024). Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15429
Vancouver
Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, et al. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15429
BibTeX
@article{Rebordosa2024,
author = {Rebordosa, Cristina and Thomsen, Reimar W and Tave, Arlene K and Madsen, Morten and Beachler, Daniel C and Martinez, David and Garcia-Esteban, Raquel and Plana, Estel and Tormos, Anita and Farsani, Soulmaz Fazeli and Perez-Gutthann, Susana and Pladevall-Vila, Manel},
title = {Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15429}
}
EUVIMED